Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial-Reference-Cited by-同舟云学术

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

Published:2023-02 Issue:1 Volume:8 Page:100772
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

de Azambuja E.,Agostinetto E.,Procter M.,Eiger D.,Pondé N.,Guillaume S.,Parlier D.,Lambertini M.,Desmet A.,Caballero C.,Aguila C.,Jerusalem G.,Walshe J.M.,Frank E.,Bines J.,Loibl S.,Piccart-Gebhart M.,Ewer M.S.,Dent S.,Plummer C.,Suter T.

Funder

Roche

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Systemic treatment of patients with early breast cancer: recent updates and state of the art1;Caparica;The Breast,2019

2. The changing paradigm for the treatment of HER2-positive breast cancer;Patel;Cancers (Basel),2020

3. Trastuzumab containing regimens for early breast cancer;Moja;Cochrane Database Syst Rev,2012

4. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials;de Azambuja;Breast Cancer Res Treat,2020

5. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity;Ewer;J Clin Oncol,2005

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update;Journal of Clinical Oncology;2024-09-11

2. Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community;Breast Cancer;2024-08-13

3. A Comprehensive Review on the State of the Art of Breast Cancers in Italy;Current Medicinal Chemistry;2024-06

4. Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks);Breast Cancer Research and Treatment;2024-05-20

5. GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy;Frontiers in Pharmacology;2024-05-17